We envision a better way.

We

Impel NeuroPharma strives to create life-changing innovative therapies for CNS diseases

Discover More

What We Do

Impel NeuroPharma is focused on developing transformative therapies for people living with central nervous system (CNS) disorders through the pioneering of an optimized approach to drug delivery. Our investigational therapies are enabled by the Company’s proprietary upper nasal delivery technology, known as the Precision Olfactory Delivery, or POD®, device.

The upper nasal space is surrounded by a rich vasculature that has the potential for injection-like absorption, resulting in more rapid and consistent bioavailability and clinical response. While an ideal target for drug delivery, to date no technology has been able to consistently deliver drugs predictably and consistently to the upper nasal area.

Impel NeuroPharma is investigating utilizing its performance technology to deliver proven treatments for neurological conditions, including migraine, OFF episodes in Parkinson’s disease and acute agitation associated with schizophrenia, bipolar I disorder and autism.

Press Releases

Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the…

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for…

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for…

References

1 Data on File